Longeveron LLC

LGVN · NASDAQ · Healthcare / Biotechnology

2.49USD-0.48 (-16.16%)

Price History

Full chart

Market Stats

Previous Close2.97

Open2.90

Day Range2.40 – 2.90

52-Week Range2.30 – 12.30

Volume60.38K

Market Cap8.38M

P/E (TTM)0.00

Forward P/E0.00

EPS-9.39

Dividend Yield0.00%

Beta-0.26

50-Day Avg6.31

200-Day Avg7.08

About

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Stephen H. Willard Esq.
Employees38
HeadquartersLife Science & Technology Park, Miami, FL, United States, 33136, USA
Websitehttps://longeveron.com

Leadership

Dr. Joshua Michael Hare FACC, M.D.Co-Founder, Chief Science Officer & Executive Chairman · b. 1963
Mr. Paul T. Lehr J.D.General Counsel & Secretary · b. 1968
Mr. Stephen H. Willard Esq.CEO & Director · b. 1961
Mr. Nirav Suresh Jhaveri C.F.A., M.B.A.CFO and Principal Financial & Accounting Officer · b. 1978
Mr. Devin BlassCTO and Senior VP of Chemistry, Manufacturing & Controls · b. 1986
Dr. Nataliya Agafonova M.D.Chief Medical Officer · b. 1970
Ms. Lisa McClain-MossVice President of Manufacturing · b. 1971
Ms. Marie WashburnVP & Corporate Controller · b. 1975
Mr. Brian G Rash Ph.D.Vice President of Research & Discovery

Financials

Income Statement

Currency: USD	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	2.13M	5.63M	5.63M	1.31M	1.22M	709.00K	2.39M	1.20M
Growth (%)	-	+163.71%	-0.01%	-76.80%	-6.43%	-41.98%	+237.38%	-49.87%
Cost of Revenue	1.45M	3.80M	3.80M	716.00K	725.00K	488.00K	508.00K	396.00K
Gross Profit	680.65K	1.83M	1.83M	590.00K	497.00K	221.00K	1.88M	803.00K
Gross Margin	31.88%	32.44%	32.44%	45.18%	40.67%	31.17%	78.76%	66.97%
Operating Expense	7.04M	5.60M	5.60M	18.05M	18.54M	21.25M	18.41M	24.09M
Operating Income	-6.36M	-3.78M	-3.78M	-17.46M	-18.04M	-21.03M	-16.52M	-23.29M
Operating Margin	-297.95%	-67.12%	-67.12%	-1336.60%	-1476.51%	-2966.01%	-690.72%	-1942.20%
EBITDA	-5.59M	-2.95M	-2.93M	-16.13M	-17.94M	-20.47M	-15.02M	-21.48M
EBITDA Margin	-261.90%	-52.32%	-52.03%	-1234.84%	-1468.25%	-2886.74%	-627.72%	-1791.24%
Net Income	-6.34M	-3.72M	-3.72M	-17.05M	-18.84M	-21.41M	-15.97M	-22.70M
Net Income Margin	-296.84%	-66.09%	-66.10%	-1305.13%	-1541.33%	-3020.17%	-667.77%	-1893.58%
R&D	3.88M	2.67M	2.67M	7.09M	9.37M	9.07M	8.14M	12.04M
R&D as % of Total Revenue	181.56%	47.51%	47.50%	543.03%	766.78%	1278.70%	340.18%	1004.25%
Interest Expense	0	169	6.54K	4.00K	287.00K	-	-	-
Interest Expense % of Total Revenue	0.00%	0.00%	0.12%	0.31%	23.49%	-	-	-

Balance Sheet

Currency: USD	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	10.52M	10.58M	9.24M	42.77M	27.41M	12.08M	25.56M	10.26M
Total Liabilities	3.71M	6.14M	7.28M	5.31M	6.91M	5.34M	3.67M	4.59M
Total Equity	6.81M	4.45M	1.96M	37.45M	20.50M	6.74M	21.89M	5.67M
Cash	4.03M	1.87M	816.00K	25.66M	10.50M	4.95M	19.23M	4.66M
Total Debt	-	4.14M	4.14M	3.14M	2.60M	2.04M	1.45M	824.00K
Net Debt	-4.03M	2.27M	3.33M	-22.52M	-7.90M	-2.91M	-17.79M	-3.84M

Cash Flow

Currency: USD	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-5.18M	-2.39M	-2.36M	-9.64M	-13.97M	-19.00M	-13.87M	-18.64M
Investing Cash Flow	-211.68K	-125.05K	-261.50K	-10.70M	-677.00K	8.19M	-640.00K	-595.00K
Financing Cash Flow	1.35M	350.00K	1.58M	45.17M	-509.00K	5.26M	28.79M	4.67M
Capital Expenditure	211.68K	37.57K	261.50K	1.31M	856.00K	301.00K	992.00K	245.00K
Free Cash Flow	-5.39M	-2.43M	-2.63M	-10.95M	-14.82M	-19.30M	-14.86M	-18.89M
Dividends Paid	-	-	-	451.00K	-	-	8.65M	-
FCF to OCF	104.09%	101.57%	111.06%	113.59%	106.13%	101.58%	107.15%	101.31%
Dividend Paid to FCF	-	-	-	-4.12%	-	-	-58.21%	-

Earnings

Report Date	Dec 31, 2019	Jun 30, 2020	Sep 30, 2020	Dec 31, 2020	Jan 19, 2021	May 14, 2021	Aug 13, 2021	Dec 22, 2021	Mar 11, 2022	May 13, 2022	Aug 12, 2022	Nov 14, 2022	Mar 10, 2023	May 12, 2023	Aug 11, 2023	Nov 9, 2023	Feb 27, 2024	May 14, 2024	Aug 14, 2024	Nov 12, 2024	Feb 28, 2025	May 8, 2025	Aug 13, 2025	Nov 4, 2025	Mar 18, 2026	May 13, 2026	Aug 12, 2026	Nov 3, 2026
EPS Estimate	0.00	0.00	0.00	0.00	0.00	-	-	-	-0.25	-2.25	-2.27	-2.20	-2.00	-0.21	-2.47	-2.40	-2.05	-2.00	-0.87	-0.44	-0.20	-0.33	-0.35	-0.26	-3.67	-0.17	-0.19	-1.70
EPS Actual	-0.23	-0.08	-0.06	-0.66	-0.03	-0.18	-0.26	-0.25	-0.20	-1.70	-2.70	-2.50	-2.10	-0.22	-2.70	-2.80	-2.50	-1.61	-1.83	-0.34	-0.27	-0.34	-0.33	-0.39	-2.20	-0.19	-0.19	-
Surprise	-	-	-	-	-	-	-	-	20.00%	24.44%	-18.94%	-13.64%	-5.00%	-4.76%	-9.31%	-16.67%	-21.95%	19.50%	-110.34%	22.73%	-35.00%	-3.03%	5.71%	-50.00%	40.00%	-11.76%	0.00%	-
Timing	-	-	-	-	-	-	-	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	After-hours	After-hours	After-hours	After-hours	After-hours	-	After-hours	After-hours	After-hours	-	After-hours	After-hours	-

Key Statistics & Ratios

Market Cap8.38M

Enterprise Value-1.21M

Trailing P/E0.00

Forward P/E0.00

Price / Sales7.06

Price / Book0.80

EPS-9.39

Book Value3.28

Revenue (TTM)1.19M

Gross Profit (TTM)828.00K

EBITDA-22.44M

Profit Margin0.00%

Operating Margin-2150.17%

Return on Equity-203.61%

Return on Assets-90.95%

Shares Outstanding3.04M

Shares Float2.38M

Beta-0.26

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Buy

Based on 3 analystsTarget 61.25

Buy
3

Ownership Breakdown

Institutions: 22.64%
Insiders: 15.14%
Retail / Other: 62.22%

Top Institutional Holders

Millennium Management LLC
1.35M4.25%
Logos Global Management LP
1.29M4.04%
Vanguard Capital Management, LLC
542.03K1.70%
BlackRock Inc
224.20K0.70%
Geode Capital Management, LLC
203.62K0.64%
ADAR1 Capital Management LLC
200.00K0.63%
Jane Street Group LLC
185.66K0.58%
HRT FINANCIAL LLC
118.89K0.37%
Beacon Pointe Advisors, LLC
100.00K0.31%
State Street Corp
45.38K0.14%
Vanguard Fiduciary Trust Co
38.72K0.12%
Capital Investment Advisory Services, LLC
26.52K0.08%
Commonwealth Equity Services, LLC
25.16K0.08%
Hamilton Point Investment Advisors, LLC
22.45K0.07%
Moneta Group Investment Advisors Inc
21.30K0.07%

Top Fund Holders

Vanguard MStar Total Stk Mkt Idx Invest
36.13K1.13%
Fidelity Extended Market Index
135.40K0.42%
Abante Quant Value FI
75.96K0.24%
Fidelity Total Market Index
23.93K0.07%
Fidelity Series Total Market Index
20.40K0.06%

Stock Splits

Aug 27, 20261:10
Mar 27, 20241:10